1374639-75-4

Basic information

• Product Name: LEE011 (succinate)
• Synonyms: LEE011 (succinate);7-cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate;LEE-011 succinate salt, Ribociclib succinate salt;Ribociclib succinate
• CAS NO: 1374639-75-4
• Molecular Formula: C27H36N8O5
• Molecular Weight: 552.62534
• Mol File: 1374639-75-4.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: LEE011 (succinate)(CAS DataBase Reference)
• NIST Chemistry Reference: LEE011 (succinate)(1374639-75-4)
• EPA Substance Registry System: LEE011 (succinate)(1374639-75-4)

Safety Data

• Hazardous Substances Data: 1374639-75-4(Hazardous Substances Data)

Usage

Description

LEE011 (succinate) is a potent and selective CDK4/6 inhibitor with oral bioavailability, designed to target and inhibit the activity of cyclin-dependent kinases 4 and 6, which play a crucial role in cell cycle regulation and are often dysregulated in various cancers.

Uses

Used in Pharmaceutical Industry:
LEE011 (succinate) is used as an anti-cancer agent for its ability to inhibit the CDK4/6 proteins, which are commonly overactive in cancer cells. This inhibition can help control the unregulated cell division and growth associated with cancer.
Used in Combination Therapy for Melanoma and Breast Cancer:
In combination with LGX818 (a V600E BRAF specific inhibitor) or BYL719 (a PIK3CA specific inhibitor), LEE011 (succinate) is used to enhance anti-tumor activity in melanoma and breast cancer tumor models. The synergistic effect of these drugs can lead to more robust anti-cancer responses and potentially improve patient outcomes.

Upstream product

• 1374639-78-7 N,N‐dimethyl‐7‐cyclopentyl‐2‐{[5‐(4-tert-butoxycarbonylpiperazin‐1‐yl)pyridin‐2‐yl]amino}‐7H‐pyrrolo[2,3‐d]pyrimidine‐6‐carboxamide 
• 110-15-6 succinic acid 
• 1211441-98-3 (7-cyclopentyl-Ν,Ν-dimethyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrrolo [2,3-d]pyrimidine-6-carboxamide) 
• 52092-47-4 5-chloro-2-nitropyridine 
• 775288-71-6 1-(6-nitropyridin-3-yl)piperazine 
• 1195-08-0 2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde 
• 1211443-58-1 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid 
• 571189-16-7 4-(6-nitropyridin-3-yl)-piperazine-1-carboxylic acid tert-butyl ester 
• 39856-50-3 5-bromo2-nitropyridine 
• 571188-59-5 tert-butyl 4-(6-aminopyridin-3-yl)piperazine-1-carboxylate 
• 1211443-61-6 2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide 
• 1374639-77-6 (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol 
• 1374639-76-5 3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-yl)prop-2-yn-1-ol 

Relevant articles and documents

POLYMORPHS OF 7-CYCLOPENTYL-N,N-DIMETHYL-2-{[5-(PIPERAZIN-1-YL) PYRIDIN-2-YL]-AMINO}-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to novel crystalline forms of butanedioic acid 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl) pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide of formula-1a and process for preparation thereof. The present invention also relates to a process for the preparation of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide. Further, the present application also relates to acid addition salts of 7-cyclopentyl-N,N-dimethyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}-7H-pyrrolo[2,3-d] pyrimidine-6-carboxamide and process for the preparation thereof.

RIBOCICLIB INTERMEDIATE AND PROCESS FOR PREPARATION THEREOF

The present invention relates to the process for the preparation of ribociclib succinate by making use of novel intermediates. The invention also relates to the process for the preparation of novel intermediates.

Crystal form of and preparation method and application thereof (by machine translation)

The invention relates to a crystal form of, a preparation method and an application thereof. , The invention provides a plurality of novel crystal forms and a preparation method thereof, and the novel crystal forms disclosed by the invention have excellent solubility and the like. (by machine translation)